| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥44.2B | ¥47.4B | -6.8% |
| Operating Income | ¥9.9B | ¥10.0B | -0.5% |
| Ordinary Income | ¥9.8B | ¥9.9B | -1.5% |
| Net Income | ¥7.7B | ¥6.9B | +10.4% |
| ROE | 13.3% | 12.4% | - |
FY2026 Q3 consolidated results showed mixed performance with revenue declining 6.8% YoY to 4,420 million yen while maintaining profitability. Operating income remained nearly flat at 992 million yen (-0.5% YoY), reflecting an operating margin of 22.4%. Ordinary income decreased 1.5% to 976 million yen. Net income increased 10.4% YoY to 766 million yen, supported by investment securities gains of 48 million yen. The revenue decline primarily reflects a strategic shift in the Technology Consulting segment, which deliberately curtailed short-term, small-scale projects to prioritize AI-driven development infrastructure buildout using IBM watsonx, while the Medical segment achieved record operating income growth. Total assets decreased to 76.9 billion yen from 78.7 billion yen, with equity strengthening to 57.7 billion yen from 56.0 billion yen.
Revenue declined 6.8% YoY to 4,420 million yen, driven by a 13.5% decline in Technology Consulting segment revenue to 2,999 million yen. This decline was strategic rather than market-driven: the parent company in Japan deliberately reduced acceptance of short-term, small-scale projects to prioritize training approximately 50 AI engineers and building AI-driven development capabilities using IBM watsonx. Management estimated this strategic shift resulted in approximately 70 million yen profit reduction in Q3. Conversely, the Medical segment posted 11.7% revenue growth to 1,421 million yen, achieving record quarterly operating income.
Operating income decreased marginally by 0.5% to 992 million yen despite the revenue decline, demonstrating strong operational discipline. The operating margin improved to 22.4% from 21.1% in the prior year. This margin resilience was supported by the high-margin Medical segment (operating margin 63.2%, up from 65.1% prior year) and cost structure improvements at the Philippine subsidiary within Technology Consulting, which achieved 25.2% operating profit growth despite 2.9% revenue decline through direct contract expansion and cost rationalization.
The gap between ordinary income (976 million yen) and net income (766 million yen) reflects ordinary tax expense of 259 million yen. Non-recurring factors include investment securities sale gains of 48 million yen recorded in extraordinary income, which contributed to the 10.4% net income growth despite flat operating performance. Management noted that US tariff impacts, initially estimated at 60 million yen profit reduction in Q1-Q2, proved less severe than anticipated.
This represents a "revenue down, profit flat" pattern, with profit maintained through margin management and strategic prioritization of long-term growth infrastructure over short-term revenue maximization.
Medical segment is the core business by operating profit contribution, generating 898 million yen in operating income (90.5% of total segment operating profit) on revenue of 1,421 million yen. Revenue grew 11.7% YoY and operating income increased 8.1%, achieving record quarterly profit. The segment maintained an exceptional operating margin of 63.2% despite absorbing PMI costs from the ISM acquisition and new product development investments. The Mighty series user base expanded to 22,671 locations (up 727), capturing approximately 49% share in hospitals and 18% in clinics. Customer retention remained at 99.6%. Management expects full profit contribution from the ISM acquisition to materialize from Q4 onward following PMI completion.
Technology Consulting segment generated operating income of 290 million yen (9.5% of segment total) on revenue of 2,999 million yen, representing declines of 34.4% and 13.5% respectively. However, this performance reflects deliberate strategic repositioning rather than business deterioration. The Japanese parent company initiated training of approximately 50 AI engineers and began transitioning from a traditional labor-hours model to an AI-driven development framework leveraging IBM watsonx, deliberately declining short-term projects during this buildout phase. The Philippine subsidiary demonstrated the underlying business strength, achieving 25.2% operating profit growth to 268 million yen (margin 12.5%) through direct contract expansion and cost optimization, despite 2.9% revenue decline to 2,131 million yen. Management commenced PoC project acceptance in Q4, with full-scale project implementation and recurring orders planned for the next fiscal year. The AI-driven model targets approximately 1.6x productivity improvement.
The Medical segment drove overall profit growth through its high-margin recurring revenue model and M&A-driven expansion, while Technology Consulting's profit decline was a managed transition cost toward higher-value service delivery.
Profitability: ROE 13.3% (calculated as 17.4% net margin × 0.574 asset turnover × 1.33 financial leverage), operating margin 22.4% (prior year 21.1%), gross margin 42.0%, net profit margin 17.3% (benefiting from investment securities gains).
Cash Quality: Operating cash flow data not disclosed in XBRL, limiting cash quality assessment. However, cash and deposits totaled 4,904 million yen, representing 63.7% of total assets, indicating strong liquidity position.
Investment: Capital expenditure and depreciation data not available in XBRL for ratio calculation. However, management indicated M&A investments targeting 8-10 regional medical equipment distributors (several hundred million to 1 billion yen scale each) during 2025-2030, to be funded from internal cash reserves.
Financial Health: Equity ratio 75.0% (prior 71.2%), current ratio 444.3%, quick ratio 444.3%, demonstrating exceptional financial stability. Interest-bearing debt minimal at 102 million yen (short-term borrowings only), resulting in debt-to-equity ratio of 0.018 and debt-to-capital ratio of 1.7%. Interest coverage ratio 151.96x.
Efficiency: Days sales outstanding approximately 113 days (accounts receivable 1,370 million yen / quarterly revenue), indicating extended collection periods. Days payable outstanding declined significantly as accounts payable decreased 57.2% from 130 million yen to 56 million yen, reflecting changes in payment terms or procurement structure.
Operating cash flow data not disclosed in XBRL for the quarter, preventing direct analysis of cash conversion quality. The relationship between operating cash flow and net income of 766 million yen cannot be verified.
Investing and financing cash flow details not available in XBRL. However, balance sheet changes show cash and deposits at 4,904 million yen (63.7% of total assets), down from prior period but remaining substantial. Investment securities sale resulted in 48 million yen gain, indicating partial portfolio liquidation.
Free cash flow cannot be calculated due to missing operating and investing cash flow data.
Cash generation quality: Assessment limited by data availability. However, the combination of strong net income (766 million yen), minimal debt (102 million yen), and substantial cash reserves (4,904 million yen) suggests adequate cash generation capability. The Medical segment's 99.6% customer retention rate and subscription-based revenue model supports recurring cash flow. Management's stated policy to fund M&A strategy through internal cash reserves implies confidence in cash generation sustainability. Warrants monitoring through quarterly operating cash flow disclosure.
Ordinary income of 976 million yen and net income of 766 million yen show reasonable alignment after considering income taxes of 259 million yen. Non-recurring items totaled 48 million yen from investment securities sales recorded as extraordinary income, representing 6.3% of net income or 1.1% of revenue. While modest, this gain contributed to the 10.4% net income growth against flat operating performance.
The gap between operating income (992 million yen) and ordinary income (976 million yen) of 16 million yen primarily reflects net non-operating expenses, which is minimal relative to operating profit. Interest expense was 6.5 million yen, easily covered by operating income (coverage ratio 151.96x).
Management clearly identified approximately 70 million yen in foregone profit from Technology Consulting due to strategic curtailment of short-term projects for AI engineer training, representing a deliberate investment in future capability. Additionally, PMI costs from the ISM acquisition were absorbed within the Medical segment's Q3 results, with full profit contribution expected from Q4 onward.
Operating cash flow data not available for accruals analysis. The substantial increase in days sales outstanding (approximately 113 days) compared to industry norms raises a potential earnings quality concern if collections are deteriorating. However, the Medical segment's 99.6% retention rate suggests collection risk may be limited to payment timing rather than credit quality. This warrants monitoring.
Core earnings quality appears solid given high operating margins (22.4%), strong gross margins (42.0%), and management's transparent disclosure of temporary profit reduction factors. Non-recurring gains are minor. Primary concern is verification of cash conversion, which requires operating cash flow disclosure.
Full-year guidance remains unchanged at revenue 6,572 million yen (+3.6% YoY), operating income 1,351 million yen (+2.7%), ordinary income 1,364 million yen (+1.7%), and net income 948 million yen (+10.5%). Dividend forecast maintained at 40 yen per share.
Q3 cumulative progress versus full-year guidance: Revenue progress rate not directly calculable from provided data (Q3 quarterly revenue 4,420 million yen provided rather than cumulative). Using quarterly figure as proxy suggests Q3 represents 67.3% of full-year revenue guidance, which is behind the standard 75% Q3 pace. This implies Q4 must deliver substantial recovery, consistent with management's explanation that Technology Consulting PoC projects commence in Q4 and Medical segment ISM acquisition delivers full profit contribution post-PMI completion.
Operating income quarterly figure (992 million yen) represents 73.4% of full-year guidance (1,351 million yen), slightly behind the 75% standard Q3 pace but within reasonable range given Q4 catalysts.
The unchanged guidance despite Q3 revenue underperformance reflects management confidence in: (1) Medical segment momentum from completed PMI and ongoing M&A strategy, (2) Technology Consulting PoC project pipeline commencing in Q4, and (3) mitigation of US tariff impacts below initial estimates. The revenue recovery assumption appears aggressive given the required Q4 acceleration, warranting close monitoring of Technology Consulting PoC conversion and Medical segment M&A contribution timing.
Annual dividend forecast maintained at 40 yen per share for fiscal year ending March 2026. Based on net income of 766 million yen (Q3 quarterly) and annualized share count, the indicated payout ratio is approximately 64.0% as stated by the company. Management articulated a two-tier dividend policy: stable base dividend of 25 yen per share plus performance-linked component, targeting payout ratio above 50% to balance stable returns with sharing business growth benefits.
The 40 yen dividend represents continuation from prior practice. With cash and deposits of 4,904 million yen and minimal debt (102 million yen), the company possesses substantial capacity to fund dividends. However, sustainability assessment is constrained by lack of operating cash flow disclosure. The stated payout ratio of 64% is elevated, leaving limited retained earnings margin if business conditions deteriorate.
No share buyback program disclosed in the materials. Total return ratio equals payout ratio of approximately 64%.
The dividend policy appears sustainable in the near term given strong cash reserves, but medium-term sustainability depends on operating cash flow generation, particularly as management pursues M&A strategy targeting 8-10 acquisitions requiring several hundred million to 1 billion yen each during 2025-2030. Management's commitment to fund M&A through internal cash implies prioritization of growth investment, which could constrain dividend growth despite the performance-linked policy component.
Near-term: (1) Q4 completion of ISM acquisition PMI with full profit contribution to Medical segment; (2) Commencement of Technology Consulting PoC project acceptance in Q4 following AI engineer training program; (3) Progress on next Medical segment M&A candidate negotiations currently underway; (4) Completion of transition to Tokyo Stock Exchange Standard Market (completed February 5, 2026 as reported).
Long-term: (1) Medical segment M&A strategy targeting 8-10 regional distributor acquisitions (several hundred million to 1 billion yen scale each) during 2025-2030 to build nationwide direct sales model and maximize customer lifetime value; (2) Technology Consulting transition from labor-hours model to AI-driven development framework leveraging IBM watsonx, targeting 1.6x productivity improvement and progression from PoC to full implementation projects with recurring revenue from next fiscal year; (3) Medical segment Mighty series market share expansion from current 49% hospital and 18% clinic penetration with 99.6% retention rate; (4) Technology Consulting Philippine AI Center establishment and integration of watsonx into ACTION new graduate training program for specialized AI talent development; (5) Cross-selling opportunities between Medical segment's expanded distributor network post-M&A and existing product portfolio including MightyChecker EX and Mighty QUBE Hybrid.
Industry Position (Reference - Proprietary Analysis)
Profitability: Operating margin 22.4% substantially exceeds IT/Telecom industry median of 8.0% (IQR 3.4%-17.4%, Q3 2025, n=99 companies), placing the company in the top quartile. Net profit margin 17.4% (annualized) also significantly exceeds industry median of 5.6% (IQR 2.2%-12.0%), ranking among industry leaders. ROE 13.3% exceeds industry median of 8.2% (IQR 3.5%-13.3%), positioning near the upper quartile.
Efficiency: Asset turnover 0.574x is below industry median of 0.68 (IQR 0.52-0.95), reflecting the company's high-margin, capital-light business model rather than efficiency concerns. Days sales outstanding of approximately 113 days significantly exceeds industry median receivables turnover of 60.53 days (IQR 45.96-79.94), representing a notable collection period extension that warrants monitoring.
Financial Health: Equity ratio 75.0% exceeds industry median of 59.5% (IQR 43.7%-72.8%), demonstrating exceptional financial stability. Current ratio 444.3% far exceeds industry median of 2.13x (IQR 1.56x-3.58x), indicating extremely strong liquidity position.
Growth: Revenue decline of 6.8% YoY underperforms industry median revenue growth of 10.5% (IQR -1.6% to 20.5%), placing the company in the bottom quartile. However, this reflects deliberate strategic curtailment of low-margin Technology Consulting projects rather than market share loss.
The company exhibits superior profitability and financial health metrics relative to IT/Telecom industry peers, trading revenue growth for margin quality. The extended receivables collection period represents the primary metric requiring attention relative to industry norms.
Industry: IT/Telecom sector (99 companies), Comparison period: Q3 2025, Source: Proprietary analysis
Business Model Transition Risk: Technology Consulting segment's shift from traditional labor-hours model to AI-driven development using IBM watsonx represents significant execution risk. The segment deliberately curtailed approximately 70 million yen in Q3 profit to invest in training 50 AI engineers. Success depends on converting PoC projects (commencing Q4) into full implementation and recurring revenue from next fiscal year, achieving targeted 1.6x productivity improvement, and winning high-value projects in competitive AI services market. Failure to execute could result in sustained revenue decline without offsetting margin improvement.
Extended Receivables Collection Risk: Days sales outstanding of approximately 113 days significantly exceeds industry median of 60.53 days, representing 86% longer collection period than typical industry practice. While Medical segment's 99.6% retention rate suggests limited credit risk, the extended collection timing ties up working capital and creates cash flow timing mismatches. Quality alert flagged receivables collection delay. If DSO extends further or customer payment issues emerge, cash conversion of reported profits could deteriorate despite strong net income.
M&A Execution and Integration Risk: Medical segment growth strategy targets 8-10 acquisitions of regional distributors (several hundred million to 1 billion yen each) during 2025-2030. The ISM acquisition absorbed PMI costs in Q3 with profit contribution expected from Q4 onward. Multiple simultaneous integrations could strain management bandwidth, divert resources from organic growth, and result in slower-than-expected synergy realization or cultural integration challenges. Each acquisition valued at several hundred million to 1 billion yen represents material deployment of the company's 4,904 million yen cash reserves. Failed integration or overpayment could impair returns. Additionally, 100% short-term debt ratio (though absolute debt is minimal at 102 million yen) creates refinancing monitoring requirement.
Strategic Positioning for Long-term Value Creation Over Short-term Maximization: The FY2026 Q3 results demonstrate management's deliberate prioritization of sustainable profit growth infrastructure over near-term revenue optimization. Technology Consulting accepted approximately 70 million yen profit reduction to build AI-driven development capabilities targeting 1.6x productivity improvement, while Medical segment absorbed ISM acquisition PMI costs while achieving record operating income. This strategic patience is evidenced by maintaining 22.4% operating margin despite 6.8% revenue decline, suggesting confidence in future margin expansion as investments mature. The approach contrasts with typical quarterly earnings management and reflects multi-year value creation orientation.
Exceptional Margin Profile with Capital-Efficient Growth Model: Operating margin of 22.4% places the company in the top quartile of IT/Telecom industry peers (median 8.0%), driven by Medical segment's exceptional 63.2% margin on subscription-based recurring revenue with 99.6% retention. Combined with equity ratio of 75.0% (versus industry median 59.5%) and minimal debt (1.7% debt-to-capital ratio), the company demonstrates rare combination of high profitability and financial flexibility. Management's stated M&A funding through internal cash (4,904 million yen reserves) rather than external financing indicates ability to pursue growth without equity dilution or leverage increase, positioning for sustainable expansion while maintaining margins.
Revenue Recovery Execution Critical to Guidance Achievement: Full-year guidance assumes Q4 revenue acceleration to offset Q3's 6.8% decline and achieve 3.6% full-year growth. This recovery depends on: (1) Technology Consulting PoC project conversion commencing Q4 and building pipeline for next fiscal year full implementations, (2) Medical segment ISM acquisition delivering full post-PMI profit contribution from Q4, and (3) potential near-term M&A completion from current candidate negotiations. The 40 yen dividend (64% payout ratio) and M&A strategy (targeting 8-10 acquisitions requiring several hundred million to 1 billion yen each) assume successful execution of this revenue inflection. Monitoring points include Technology Consulting PoC win rates and Medical M&A deal completion timing in coming quarters.
This report was automatically generated by AI integrating XBRL earnings data and PDF presentation materials as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.